Pengpeng Xu
-
- Lymphoma Diagnosis and Treatment 47
- Oncology top 10%
- CAR-T cell therapy research 21
- Viral-associated cancers and disorders 12
- Cancer Research top 10%
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 14
-
- Immune Cell Function and Interaction 10
-
- CNS Lymphoma Diagnosis and Treatment 5
-
- Cancer-related gene regulation 5
-
- Stroke Rehabilitation and Recovery 4
- Co-authors
- Shu ChengWeili ZhaoLi WangDi FuJinyan HuangYing FangHongmei YiMengyuan Ji
- Journals
- Blood (11 papers)Signal Transduction and Targeted Therapy (5 papers)Scientific Reports (4 papers)
- Partner nations
- ChinaFranceUnited States
In The Last Decade
Pengpeng Xu
73 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Pathology and Forensic Medicine 387
- Oncology 396
- Cancer Research 186
- Genetics 108
- Immunology 209
Countries citing papers authored by Pengpeng Xu
This map shows the geographic impact of Pengpeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pengpeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pengpeng Xu more than expected).
Fields of papers citing papers by Pengpeng Xu
This network shows the impact of papers produced by Pengpeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pengpeng Xu. The network helps show where Pengpeng Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pengpeng Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 7 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 4 | |
| 7 | 2023 | 18 | |
| 8 | 2023 | 10 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 46 | |
| 11 | 2022 | 6 | |
| 12 | 2022 | 6 | |
| 13 | 2022 | 11 | |
| 14 | 2021 | 24 | |
| 15 | 2021 | 30 | |
| 16 | 2021 | 9 | |
| 17 | 2019 | 7 | |
| 18 | 2019 | 1 | |
| 19 | 2017 | 6 | |
| 20 | 2015 | 2 |
About Pengpeng Xu
Pengpeng Xu is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 83 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (47 papers), CAR-T cell therapy research (21 papers), Chronic Lymphocytic Leukemia Research (14 papers), Viral-associated cancers and disorders (12 papers), Immune Cell Function and Interaction (10 papers), CNS Lymphoma Diagnosis and Treatment (5 papers), Cancer-related gene regulation (5 papers) and Stroke Rehabilitation and Recovery (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (387 citations), Oncology (396 citations) and Cancer Research (186 citations). Pengpeng Xu has collaborated with scholars based in China, France and United States. Frequent co-authors include Shu Cheng, Weili Zhao, Li Wang, Di Fu, Li Wang, Jinyan Huang, Ying Fang, Hongmei Yi, Mengyuan Ji and Yao‐Hui Huang. Their work appears in journals such as Blood, Signal Transduction and Targeted Therapy, Scientific Reports, EBioMedicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.